ReviewDrugs2009
Lacosamide: in partial-onset seizures.
Review in Drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 55 citations in OpenAlex.
- Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability.Journal of neurology · 2011Trial
- Investigating the Relationship Between Anti-seizure Medications and Bleeding Disorders: A Comprehensive Review of the Current Literature.Drugs - real world outcomes · 2025Review
- The Effect of Anti-seizure Medications on the Propagation of Epileptic Activity: A Review.Frontiers in neurology · 2021Review
- Review
- Lacosamide Inhibition of Nav1.7 Voltage-Gated Sodium Channels: Slow Binding to Fast-Inactivated States.Molecular pharmacology · 2017Article
- The Safety and Effectiveness of Intravenous Lacosamide for Refractory Status Epilepticus in the Critically Ill.Neurocritical care · 2017Article
- Treatment of Convulsive Status Epilepticus.Current treatment options in neurology · 2016Article
- Review
- Lacosamide modulates interictal spiking and high-frequency oscillations in a model of mesial temporal lobe epilepsy.Epilepsy research · 2015Article
- Lacosamide: a review of its use as adjunctive therapy in the management of partial-onset seizures.CNS drugs · 2013Review
- The safety of lacosamide for treatment of seizures and seizure prophylaxis in adult hospitalized patients.The Neurohospitalist · 2012Article
- The use of lacosamide in refractory status epilepticus.Neurocritical care · 2011Article
- Review
- A comprehensive review of the literature on epilepsy in selected countries in emerging markets.Neuropsychiatric disease and treatment · 2011Article
- Lacosamide for the prevention of partial onset seizures in epileptic adults.Neuropsychiatric disease and treatment · 2010Article
- Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety.Therapeutics and clinical risk management · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lacosamide is a functionalized amino acid, the antiepileptic effects of which appear to be due to a novel mode of action, namely the selective enhancement of slow inactivation of voltage-gated sodium channels. Lacosamide is available as oral or intravenous formulations. Bioequivalence between the oral tablet and the oral syrup of lacosamide has been established. The bioavailability of the oral lacosamide tablet was similar to that of a 30- or 60-minute intravenous infusion of lacosamide administered at the same dosage. Oral lacosamide when added concomitantly with between one and three antiepileptic drugs was effective in adult patients with uncontrolled partial-onset seizures with or without secondary generalization, according to pooled data (n = 1308) from three phase II/III studies that had a 12-week maintenance phase. The percentage of patients with a >or=50% reduction from baseline to the maintenance phase in seizure frequency was significantly greater with oral lacosamide 200 or 400 mg/day (34% and 40%) than with placebo (23%). The median percentage reduction in seizure frequency per 28 days from baseline to the maintenance phase was significantly greater with lacosamide 400 mg/day than with placebo in each of the three phase II/III studies. Lacosamide was generally well tolerated in adult patients with partial-onset seizures, with most treatment-emergent adverse events being of mild or moderate severity. Dizziness was the most common treatment-related adverse event. When used as short-term replacement for oral lacosamide, intravenous lacosamide was well tolerated when administered as a 15-, 30- or 60-minute infusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.